Medical Devices

With financials improving but competition rising, medical device maker Pulmonx faces a critical audience at the BofA healthcare conference in May.

A new at-home testing system aims to unite dentists and physicians, streamlining obstructive sleep apnea treatment for millions of undiagnosed patients.

With expanded FDA clearance for its ARx SAI system, Life Spine challenges the closed-system model, offering surgeons unprecedented cross-vendor flexibility.

The pharma giant reports a net loss after a major write-down, but management points to a strong consumer division and a CDMO rebound as signs of recovery.

The Aesthetic Show returns to Vegas, blending AI and regenerative science with a focus on inclusivity, professional growth, and philanthropic purpose.

A Dubai hospital pioneers a one-time gene therapy for an adult with SMA, offering new hope to a patient population previously left with limited options.

A landmark study shows a novel device can safely treat severe artery blockages below the ankle, offering new hope for patients at risk of amputation.

Vensica Medical gets FDA clearance for a Phase 2 study of its ultrasound device that delivers botulinum toxin without needles for overactive bladder.

A new HHS agenda reopens the door for controversial peptides, just as a wave of next-gen obesity drugs threatens to upend the entire market.

A new wearable using ultrasound resonance could finally solve the accuracy and calibration problems plaguing blood pressure monitors for a billion patients.

Kiniksa raises its 2026 ARCALYST forecast after a blowout quarter, using its financial strength to advance a pipeline aimed at redefining pericarditis care.

Newbury's OSSC gains exclusive UK access to hyper-realistic spinal simulators, heralding a major shift from cadavers to advanced, risk-free training.

As it preps a first-in-human study for a deadly genetic heart disease, Nuevocor brings on gene therapy veteran Dr. Monica Shah to lead the charge.

Ascidian Therapeutics to present first human safety data for its Stargardt disease drug, a new RNA editing technology with broad potential for genetic diseases.

Moving beyond quick fixes, Alma unveils a continuous care strategy focused on long-term skin performance, signaling a major shift for the aesthetics industry.

Biotech firm Tr1X unveils promising data for its novel cell therapies, offering a scalable new approach to treating autoimmune diseases like MS and GvHD.

Umoja Biopharma's UB-VV500 aims to revolutionize myeloma care by creating a dual-antigen CAR T therapy directly inside the patient's body.

VisionSys AI is in talks for a massive $90M investment to pivot to BCI tech, but with its stock down 96%, can this lifeline conquer the final frontier?

New Phase 2a data reveals Oruka Therapeutics' ORKA-001 achieved complete skin clearance in nearly two-thirds of patients, positioning it as a potential game-changer.

A new report reveals payers are rewriting drug benefit rules, sacrificing rebates for more control as they grapple with the high cost of new therapies.